Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Staber, PB; Jurczak, W; Greil, R; Vucinic, V; Middeke, JM; Montillo, M; Munir, T; Neumeister, P; Schetelig, J; Stilgenbauer, S; Striebel, F; Dirnberger-Hertweck, M; Weirather, J; Brugger, W; Kelemen, P; Wendtner, CM; Woyach, JA.
Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitor.
Leuk Lymphoma. 2021; 62(14):3440-3451
Doi: 10.1080/10428194.2021.1964020
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Staber Philipp
- Co-Autor*innen der Med Uni Graz
- Neumeister Peter
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) whose treatment failed with a Bruton's tyrosine kinase inhibitor have poor outcomes. We investigated tafasitamab plus idelalisib (cohort A) or venetoclax (cohort B) in this patient population in a phase II study (NCT02639910). In total, 24 patients were enrolled (cohort A: n = 11, median time on study, 7.4 months; cohort B: n = 13, median time on study, 15.6 months). The most common treatment-emergent adverse event (TEAE) in cohort A was anemia (63.6%) and in cohort B was infusion-related reaction (53.8%). The most common severe TEAE was neutropenia (cohort A: 45.5%; cohort B: 46.2%). The best overall response rate was 90.9% (cohort A) and 76.9% (cohort B). Undetectable minimal residual disease in peripheral blood was achieved in 2/8 patients (cohort A) and 6/7 patients (cohort B). Overall, these results suggest that anti-CD19 antibody-based combinations may be important in the treatment of patients with CLL.
- Find related publications in this database (Keywords)
- Relapsed
- refractory chronic lymphocytic leukemia
- tafasitamab
- anti-CD19 antibody
- idelalisib
- venetoclax
- phase II study